Results 221 to 230 of about 7,636,605 (392)

Opportunities and challenges in phenotypic drug discovery: an industry perspective

Nature reviews. Drug discovery, 2017
John G. Moffat, F. Vincent, Jonathan A. Lee, J. Eder, M. Prunotto   +4 more
semanticscholar   +1 more source

Indian health activists criticise voluntary price cuts by drug industry [PDF]

, 2006
G. Mudur
openalex   +1 more source

Expert consensus on research paradigms and technological layout for clinical priority diseases in traditional Chinese medicine: Rheumatoid arthritis

Advanced Chinese Medicine, EarlyView.
Abstract Rheumatoid arthritis (RA) is a chronic, highly disabling autoimmune disease. Although modern medical treatments have made progress, challenges such as suboptimal efficacy, relapse, difficulties in comorbidity management, and side effects persist.
Dier Jin, Jinping Wang, Zihan Wang, Mei Mo, Xiaojing Liu, Nan Zhang, Xiaoxiao Zhang, Qingwen Tao, Yuan Xu   +8 more
wiley   +1 more source

Perspectives on the FDA platform technology designation program for the approval of gene therapies: a Swiss multi-stakeholder exploratory interview study. [PDF]

Orphanet J Rare Dis
Han Y, Ormond KE.
europepmc   +1 more source

Industry Practices and Compliance with U.S. Food and Drug Administration Guidelines among California Sprout Firms

, 2003
Jennifer L. Thomas, Mary S. Palumbo, Jeff Farrar, Thomas B. Farver, Dean O. Cliver   +4 more
openalex   +1 more source

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia, Stephane Rodriguez, Emilie Dugast, Christine Lebrun‐Frenay, Eric Thouvenot, Jérôme de Sèze, Emmanuelle Le Page, Sandra Vukusic, Inès Doghri, Eric Berger, Olivier Casez, Pierre Labauge, Aurélie Ruet, Catarina Raposo, Fabienne Le Frère, Arnaud B. Nicot, Sandrine Wiertlewski, Pierre‐Antoine Gourraud, Laure Michel, Laureline Berthelot, David‐Axel Laplaud   +20 more
wiley   +1 more source

Bridging academia and industry: advancing systems biology and QSP education through AstraZeneca's collaborative partnerships. [PDF]

Front Syst Biol
Pichardo-Almarza C, Kimko H.
europepmc   +1 more source

Ghost authorship of industry funded drug trials is common, say researchers [PDF]

, 2007
Sally Hargreaves
openalex   +1 more source

Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin, Gregory Sahagian, Marc H. Feinberg, C. Andrew Stewart, Christopher M. Jewell, Metin Kurtoglu, Miloš D. Miljković, Tuan Vu, Tahseen Mozaffar, James F. Howard Jr, the MG‐001 Study Group   +10 more
wiley   +1 more source

Technological and industrial trends in China's pharmaceutical sector. [PDF]

Front Pharmacol
Wang J, He M, Lu F, Chen Y, Wang H.
europepmc   +1 more source